Please login to the form below

Not currently logged in
Email:
Password:

Boehringer and Zealand focus on diabetes

Zealand Pharma and Boehringer Ingelheim have agreed an exclusive global licence and collaboration agreement for a treatment for patients with type 2 diabetes and obesity

Zealand Pharma and Boehringer Ingelheim have agreed an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and obesity.

Boehringer Ingelheim will obtain global development and commercialisation rights to ZP2929, Zealand Pharma's lead glucagon/GLP-1 dual agonist drug candidate. Zealand Pharma will be responsible for conducting the first phase I study with ZP2929 and Boehringer Ingelheim will fund the research, development and commercialisation of products under the agreement.

Zealand Pharma will be eligible to receive payments for ZP2929 and could receive additional milestone payments if other products covered by the collaboration are advanced through development. Zealand Pharma is also entitled to tiered royalties that range from high single to low double digits on global sales of products under the agreement. Zealand Pharma retains co-promotion rights in Scandinavia.

During the first two years of collaboration, Zealand Pharma is eligible to receive signature, milestone, and other payments of up to €41m including cost reimbursements and including research funding of up to €4m. 

In their research collaboration, Zealand Pharma and Boehringer Ingelheim will focus on the characterisation, identification and development of additional glucagon/GLP-1 dual agonists for the exploration of new indications, formulations and delivery systems.

Prof Dr Klaus Dugi, Boehringer Ingelheim's corporate senior vice president of medicine, said: "Our focus to develop innovative diabetes treatments is reinforced by the in-licensing of a very interesting compound from Zealand Pharma which complements Boehringer Ingelheim's pipeline in diabetes and metabolic diseases very well. 

"With our first diabetes treatment linagliptin recently approved by the FDA, we have a manifest for Boehringer Ingelheim's own research strength and its capability to bring novel medication to the patients. We are therefore pleased to bundle our R&D experience with Zealand Pharma for further projects in diabetes and obesity," he added.

16th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....

Infographics